None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Balanced high fat diet reduces cardiovascular risk in obese women although changes in adipose tissue, lipoproteins, and insulin resistance differ by race. Niswender KD, Fazio S, Gower BA, Silver HJ (2018) Metabolism : 125-134
    › Primary publication · 29382504 (PubMed)
  2. Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. Toki S, Goleniewska K, Reiss S, Zhang J, Bloodworth MH, Stier MT, Zhou W, Newcomb DC, Ware LB, Stanwood GD, Galli A, Boyd KL, Niswender KD, Peebles RS (2018) J Allergy Clin Immunol 142(5): 1515-1528.e8
    › Primary publication · 29331643 (PubMed)
  3. An insulin resistance associated neural correlate of impulsivity in type 2 diabetes mellitus. Eckstrand KL, Mummareddy N, Kang H, Cowan R, Zhou M, Zald D, Silver HJ, Niswender KD, Avison MJ (2017) PLoS One 12(12): e0189113
    › Primary publication · 29228027 (PubMed) · PMC5724830 (PubMed Central)
  4. Pulmonary vascular effect of insulin in a rodent model of pulmonary arterial hypertension. Trammell AW, Talati M, Blackwell TR, Fortune NL, Niswender KD, Fessel JP, Newman JH, West JD, Hemnes AR (2017) Pulm Circ 7(3): 624-634
    › Primary publication · 28704134 (PubMed) · PMC5841889 (PubMed Central)
  5. Leptogenic effects of NAPE require activity of NAPE-hydrolyzing phospholipase D. Chen Z, Zhang Y, Guo L, Dosoky N, de Ferra L, Peters S, Niswender KD, Davies SS (2017) J Lipid Res 58(8): 1624-1635
    › Primary publication · 28596183 (PubMed) · PMC5538284 (PubMed Central)
  6. Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core. Nance KD, Days EL, Weaver CD, Coldren A, Farmer TD, Cho HP, Niswender CM, Blobaum AL, Niswender KD, Lindsley CW (2017) J Med Chem 60(4): 1611-1616
    › Primary publication · 28103022 (PubMed)
  7. Impaired mTORC2 signaling in catecholaminergic neurons exaggerates high fat diet-induced hyperphagia. Dadalko OI, Niswender K, Galli A (2015) Heliyon 1(1): e00025
    › Primary publication · 27441217 (PubMed) · PMC4939830 (PubMed Central)
  8. The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview. Jefferson AL, Gifford KA, Acosta LM, Bell SP, Donahue MJ, Davis LT, Gottlieb J, Gupta DK, Hohman TJ, Lane EM, Libon DJ, Mendes LA, Niswender K, Pechman KR, Rane S, Ruberg FL, Su YR, Zetterberg H, Liu D (2016) J Alzheimers Dis 52(2): 539-59
    › Primary publication · 26967211 (PubMed) · PMC4866875 (PubMed Central)
  9. Imbalance in Resting State Functional Connectivity is Associated with Eating Behaviors and Adiposity in Children. Chodkowski BA, Cowan RL, Niswender KD (2016) Heliyon 2(1): e00058
    › Primary publication · 26878067 (PubMed) · PMC4750053 (PubMed Central)
  10. Disgust proneness and associated neural substrates in obesity. Watkins TJ, Di Iorio CR, Olatunji BO, Benningfield MM, Blackford JU, Dietrich MS, Bhatia M, Theiss JD, Salomon RM, Niswender K, Cowan RL (2016) Soc Cogn Affect Neurosci 11(3): 458-65
    › Primary publication · 26454815 (PubMed) · PMC4769631 (PubMed Central)
  11. Disruption of Daily Rhythms by High-Fat Diet Is Reversible. Branecky KL, Niswender KD, Pendergast JS (2015) PLoS One 10(9): e0137970
    › Primary publication · 26366733 (PubMed) · PMC4569368 (PubMed Central)
  12. mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission. Dadalko OI, Siuta M, Poe A, Erreger K, Matthies HJ, Niswender K, Galli A (2015) J Neurosci 35(23): 8843-54
    › Primary publication · 26063917 (PubMed) · PMC4461689 (PubMed Central)
  13. Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake? Russell-Jones D, Danne T, Hermansen K, Niswender K, Robertson K, Thalange N, Vasselli JR, Yildiz B, Häring HU (2015) Diabetes Obes Metab 17(10): 919-27
    › Primary publication · 25974283 (PubMed) · PMC4744774 (PubMed Central)
  14. Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation. Rojas JM, Bruinstroop E, Printz RL, Alijagic-Boers A, Foppen E, Turney MK, George L, Beck-Sickinger AG, Kalsbeek A, Niswender KD (2015) Mol Metab 4(3): 210-21
    › Primary publication · 25737956 (PubMed) · PMC4338317 (PubMed Central)
  15. PPARc activation attenuates opioid consumption and modulates mesolimbic dopamine transmission. de Guglielmo G, Melis M, De Luca MA, Kallupi M, Li HW, Niswender K, Giordano A, Senzacqua M, Somaini L, Cippitelli A, Gaitanaris G, Demopulos G, Damadzic R, Tapocik J, Heilig M, Ciccocioppo R (2015) Neuropsychopharmacology 40(4): 1052
    › Primary publication · 25668637 (PubMed) · PMC4330520 (PubMed Central)
  16. Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM). Morris LC, Nance KD, Gentry PR, Days EL, Weaver CD, Niswender CM, Thompson AD, Jones CK, Locuson CW, Morrison RD, Daniels JS, Niswender KD, Lindsley CW (2014) J Med Chem 57(23): 10192-7
    › Primary publication · 25423411 (PubMed) · PMC4266362 (PubMed Central)
  17. PPARγ activation attenuates opioid consumption and modulates mesolimbic dopamine transmission. de Guglielmo G, Melis M, De Luca MA, Kallupi M, Li HW, Niswender K, Giordano A, Senzacqua M, Somaini L, Cippitelli A, Gaitanaris G, Demopulos G, Damadzic R, Tapocik J, Heilig M, Ciccocioppo R (2015) Neuropsychopharmacology 40(4): 927-37
    › Primary publication · 25311134 (PubMed) · PMC4330506 (PubMed Central)
  18. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L (2015) Int J Obes (Lond) 39(1): 187
    › Primary publication · 25311036 (PubMed)
  19. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. Chen Z, Guo L, Zhang Y, Walzem RL, Pendergast JS, Printz RL, Morris LC, Matafonova E, Stien X, Kang L, Coulon D, McGuinness OP, Niswender KD, Davies SS (2014) J Clin Invest 124(8): 3391-406
    › Primary publication · 24960158 (PubMed) · PMC4109548 (PubMed Central)
  20. Rictor/mTORC2 facilitates central regulation of energy and glucose homeostasis. Kocalis HE, Hagan SL, George L, Turney MK, Siuta MA, Laryea GN, Morris LC, Muglia LJ, Printz RL, Stanwood GD, Niswender KD (2014) Mol Metab 3(4): 394-407
    › Primary publication · 24944899 (PubMed) · PMC4060224 (PubMed Central)
  21. Wheel-running activity modulates circadian organization and the daily rhythm of eating behavior. Pendergast JS, Branecky KL, Huang R, Niswender KD, Yamazaki S (2014) Front Psychol : 177
    › Primary publication · 24624109 (PubMed) · PMC3941004 (PubMed Central)
  22. Neurovascular unit on a chip: implications for translational applications. Alcendor DJ, Block FE, Cliffel DE, Daniels JS, Ellacott KL, Goodwin CR, Hofmeister LH, Li D, Markov DA, May JC, McCawley LJ, McLaughlin B, McLean JA, Niswender KD, Pensabene V, Seale KT, Sherrod SD, Sung HJ, Tabb DL, Webb DJ, Wikswo JP (2013) Stem Cell Res Ther : S18
    › Primary publication · 24564885 (PubMed) · PMC4029462 (PubMed Central)
  23. Consuming a balanced high fat diet for 16 weeks improves body composition, inflammation and vascular function parameters in obese premenopausal women. Silver HJ, Kang H, Keil CD, Muldowney JA, Kocalis H, Fazio S, Vaughan DE, Niswender KD (2014) Metabolism 63(4): 562-73
    › Primary publication · 24559846 (PubMed) · PMC4306330 (PubMed Central)
  24. A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptors. Morris LC, Days EL, Turney M, Mi D, Lindsley CW, Weaver CD, Niswender KD (2014) J Biomol Screen 19(6): 847-58
    › Primary publication · 24525870 (PubMed) · PMC4306651 (PubMed Central)
  25. Weight change upon once-daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin-naïve individuals with type 2 diabetes: results from the DIET trial. Niswender K, Piletic M, Andersen H, Conradsen Hiort L, Hollander P (2014) Diabetes Obes Metab 16(2): 186-92
    › Primary publication · 24112375 (PubMed)
  26. Neuronal ablation of p-Akt at Ser473 leads to altered 5-HT1A/2A receptor function. Saunders C, Siuta M, Robertson SD, Davis AR, Sauer J, Matthies HJG, Gresch PJ, Airey D, Lindsley CW, Schetz JA, Niswender KD, Veenstra-Vanderweele JM, Galli A (2014) Neurochem Int : 113-121
    › Primary publication · 24090638 (PubMed) · PMC4073299 (PubMed Central)
  27. Adipose tissue and immune function: a review of evidence relevant to HIV infection. Koethe JR, Hulgan T, Niswender K (2013) J Infect Dis 208(8): 1194-201
    › Primary publication · 23878320 (PubMed) · PMC3778969 (PubMed Central)
  28. The complex relationship between the light-entrainable and methamphetamine-sensitive circadian oscillators: evidence from behavioral studies of Period-mutant mice. Pendergast JS, Niswender KD, Yamazaki S (2013) Eur J Neurosci 38(7): 3044-53
    › Primary publication · 23869717 (PubMed) · PMC3899104 (PubMed Central)
  29. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L, NN8022-1923 Investigators (2013) Int J Obes (Lond) 37(11): 1443-51
    › Primary publication · 23812094 (PubMed)
  30. Comparison of gross body fat-water magnetic resonance imaging at 3 Tesla to dual-energy X-ray absorptiometry in obese women. Silver HJ, Niswender KD, Kullberg J, Berglund J, Johansson L, Bruvold M, Avison MJ, Welch EB (2013) Obesity (Silver Spring) 21(4): 765-74
    › Primary publication · 23712980 (PubMed) · PMC3500572 (PubMed Central)
  31. Insulin detemir attenuates food intake, body weight gain and fat mass gain in diet-induced obese Sprague-Dawley rats. Rojas JM, Printz RL, Niswender KD (2011) Nutr Diabetes : e10
    › Primary publication · 23449422 (PubMed) · PMC3302138 (PubMed Central)
  32. High-fat diet acutely affects circadian organisation and eating behavior. Pendergast JS, Branecky KL, Yang W, Ellacott KL, Niswender KD, Yamazaki S (2013) Eur J Neurosci 37(8): 1350-6
    › Primary publication · 23331763 (PubMed) · PMC3645495 (PubMed Central)
  33. A piece of my mind. Fulfilling our leadership responsibility. Gorrindo P, Tedeschi SK, Powers AR, Niswender K (2013) JAMA 309(2): 147-8
    › Primary publication · 23299605 (PubMed)
  34. Central nervous system neuropeptide Y signaling via the Y1 receptor partially dissociates feeding behavior from lipoprotein metabolism in lean rats. Rojas JM, Stafford JM, Saadat S, Printz RL, Beck-Sickinger AG, Niswender KD (2012) Am J Physiol Endocrinol Metab 303(12): E1479-88
    › Primary publication · 23074243 (PubMed) · PMC3532466 (PubMed Central)
  35. A potential role for insulin resistance in experimental pulmonary hypertension. West J, Niswender KD, Johnson JA, Pugh ME, Gleaves L, Fessel JP, Hemnes AR (2013) Eur Respir J 41(4): 861-71
    › Primary publication · 22936709 (PubMed) · PMC3746982 (PubMed Central)
  36. Neuron-specific deletion of peroxisome proliferator-activated receptor delta (PPARδ) in mice leads to increased susceptibility to diet-induced obesity. Kocalis HE, Turney MK, Printz RL, Laryea GN, Muglia LJ, Davies SS, Stanwood GD, McGuinness OP, Niswender KD (2012) PLoS One 7(8): e42981
    › Primary publication · 22916190 (PubMed) · PMC3423438 (PubMed Central)
  37. Period determination in the food-entrainable and methamphetamine-sensitive circadian oscillator(s). Pendergast JS, Oda GA, Niswender KD, Yamazaki S (2012) Proc Natl Acad Sci U S A 109(35): 14218-23
    › Primary publication · 22891330 (PubMed) · PMC3435193 (PubMed Central)
  38. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B (2013) Diabetes Obes Metab 15(1): 42-54
    › Primary publication · 22862847 (PubMed)
  39. Akt-dependent and isoform-specific regulation of dopamine transporter cell surface expression. Speed NK, Matthies HJ, Kennedy JP, Vaughan RA, Javitch JA, Russo SJ, Lindsley CW, Niswender K, Galli A (2010) ACS Chem Neurosci 1(7): 476-81
    › Primary publication · 22778840 (PubMed) · PMC3368666 (PubMed Central)
  40. CNR1 genotype influences HDL-cholesterol response to change in dietary fat intake. Silver HJ, Niswender KD, Keil CD, Jiang L, Feng Q, Chiu S, Krauss RM, Wilke RA (2012) PLoS One 7(5): e36166
    › Primary publication · 22567136 (PubMed) · PMC3342253 (PubMed Central)
  41. Tissue-specific function of Period3 in circadian rhythmicity. Pendergast JS, Niswender KD, Yamazaki S (2012) PLoS One 7(1): e30254
    › Primary publication · 22253927 (PubMed) · PMC3256228 (PubMed Central)
  42. Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons. Mazei-Robison MS, Koo JW, Friedman AK, Lansink CS, Robison AJ, Vinish M, Krishnan V, Kim S, Siuta MA, Galli A, Niswender KD, Appasani R, Horvath MC, Neve RL, Worley PF, Snyder SH, Hurd YL, Cheer JF, Han MH, Russo SJ, Nestler EJ (2011) Neuron 72(6): 977-90
    › Primary publication · 22196333 (PubMed) · PMC3246191 (PubMed Central)
  43. Impaired striatal Akt signaling disrupts dopamine homeostasis and increases feeding. Speed N, Saunders C, Davis AR, Owens WA, Matthies HJ, Saadat S, Kennedy JP, Vaughan RA, Neve RL, Lindsley CW, Russo SJ, Daws LC, Niswender KD, Galli A (2011) PLoS One 6(9): e25169
    › Primary publication · 21969871 (PubMed) · PMC3182178 (PubMed Central)
  44. Neuroendocrine regulation of food intake. Hagan S, Niswender KD (2012) Pediatr Blood Cancer 58(1): 149-53
    › Primary publication · 21953791 (PubMed)
  45. Basal insulin: beyond glycemia. Niswender KD (2011) Postgrad Med 123(4): 27-37
    › Primary publication · 21680986 (PubMed)
  46. Basal insulin: physiology, pharmacology, and clinical implications. Niswender KD (2011) Postgrad Med 123(4): 17-26
    › Primary publication · 21680985 (PubMed)
  47. Imaging body composition in obesity and weight loss: challenges and opportunities. Silver HJ, Welch EB, Avison MJ, Niswender KD (2010) Diabetes Metab Syndr Obes : 337-47
    › Primary publication · 21437103 (PubMed) · PMC3047979 (PubMed Central)
  48. Insulin signaling and addiction. Daws LC, Avison MJ, Robertson SD, Niswender KD, Galli A, Saunders C (2011) Neuropharmacology 61(7): 1123-8
    › Primary publication · 21420985 (PubMed) · PMC3518862 (PubMed Central)
  49. Effects of grapefruit, grapefruit juice and water preloads on energy balance, weight loss, body composition, and cardiometabolic risk in free-living obese adults. Silver HJ, Dietrich MS, Niswender KD (2011) Nutr Metab (Lond) 8(1): 8
    › Primary publication · 21288350 (PubMed) · PMC3039556 (PubMed Central)
  50. Insulin regulation of monoamine signaling: pathway to obesity. Niswender KD, Daws LC, Avison MJ, Galli A (2011) Neuropsychopharmacology 36(1): 359-60
    › Primary publication · 21116253 (PubMed) · PMC3055525 (PubMed Central)
  51. Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice. Siuta MA, Robertson SD, Kocalis H, Saunders C, Gresch PJ, Khatri V, Shiota C, Kennedy JP, Lindsley CW, Daws LC, Polley DB, Veenstra-Vanderweele J, Stanwood GD, Magnuson MA, Niswender KD, Galli A (2010) PLoS Biol 8(6): e1000393
    › Primary publication · 20543991 (PubMed) · PMC2882427 (PubMed Central)
  52. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Niswender K (2010) Diabetes Obes Metab 12(4): 267-87
    › Primary publication · 20380648 (PubMed)
  53. What are the risks and the benefits of current and emerging weight-loss medications? Robinson JR, Niswender KD (2009) Curr Diab Rep 9(5): 368-75
    › Primary publication · 19793507 (PubMed)
  54. Palmitic acid mediates hypothalamic insulin resistance by altering PKC-theta subcellular localization in rodents. Benoit SC, Kemp CJ, Elias CF, Abplanalp W, Herman JP, Migrenne S, Lefevre AL, Cruciani-Guglielmacci C, Magnan C, Yu F, Niswender K, Irani BG, Holland WL, Clegg DJ (2009) J Clin Invest 119(9): 2577-89
    › Primary publication · 19726875 (PubMed) · PMC2735917 (PubMed Central)
  55. Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Posey KA, Clegg DJ, Printz RL, Byun J, Morton GJ, Vivekanandan-Giri A, Pennathur S, Baskin DG, Heinecke JW, Woods SC, Schwartz MW, Niswender KD (2009) Am J Physiol Endocrinol Metab 296(5): E1003-12
    › Primary publication · 19116375 (PubMed) · PMC2681305 (PubMed Central)
  56. Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Sarruf DA, Yu F, Nguyen HT, Williams DL, Printz RL, Niswender KD, Schwartz MW (2009) Endocrinology 150(2): 707-12
    › Primary publication · 18845632 (PubMed) · PMC2646542 (PubMed Central)
  57. Obesity: increasing awareness of novel environmental factors. Niswender KD, Beech BM (2008) Diabetes 57(7): 1786-7
    › Primary publication · 18586911 (PubMed) · PMC2453635 (PubMed Central)
  58. Insulin use and weight maintenance in well-controlled type 2 diabetes: a prospective cohort study. Huizinga MM, Niswender KD, Gebretsadik T, Rothman RL, Shintani AK, Elasy TA (2008) Obesity (Silver Spring) 16(8): 1933-7
    › Primary publication · 18551124 (PubMed) · PMC2694404 (PubMed Central)
  59. Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. Stafford JM, Yu F, Printz R, Hasty AH, Swift LL, Niswender KD (2008) Diabetes 57(6): 1482-90
    › Primary publication · 18332095 (PubMed) · PMC3968924 (PubMed Central)
  60. Fish oil increases cholesterol storage in white adipose tissue with concomitant decreases in inflammation, hepatic steatosis, and atherosclerosis in mice. Saraswathi V, Gao L, Morrow JD, Chait A, Niswender KD, Hasty AH (2007) J Nutr 137(7): 1776-82
    › Primary publication · 17585030 (PubMed)
  61. Insulin action in the brain contributes to glucose lowering during insulin treatment of diabetes. Gelling RW, Morton GJ, Morrison CD, Niswender KD, Myers MG, Rhodes CJ, Schwartz MW (2006) Cell Metab 3(1): 67-73
    › Primary publication · 16399506 (PubMed)
  62. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Morton GJ, Gelling RW, Niswender KD, Morrison CD, Rhodes CJ, Schwartz MW (2005) Cell Metab 2(6): 411-20
    › Primary publication · 16330326 (PubMed)
  63. Leptin inhibits hypothalamic Npy and Agrp gene expression via a mechanism that requires phosphatidylinositol 3-OH-kinase signaling. Morrison CD, Morton GJ, Niswender KD, Gelling RW, Schwartz MW (2005) Am J Physiol Endocrinol Metab 289(6): E1051-7
    › Primary publication · 16046456 (PubMed)
  64. Leptin action in the forebrain regulates the hindbrain response to satiety signals. Morton GJ, Blevins JE, Williams DL, Niswender KD, Gelling RW, Rhodes CJ, Baskin DG, Schwartz MW (2005) J Clin Invest 115(3): 703-10
    › Primary publication · 15711637 (PubMed) · PMC548313 (PubMed Central)
  65. Adiposity signaling and biological defense against weight gain: absence of protection or central hormone resistance? Schwartz MW, Niswender KD (2004) J Clin Endocrinol Metab 89(12): 5889-97
    › Primary publication · 15579732 (PubMed)
  66. Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Niswender KD, Baskin DG, Schwartz MW (2004) Trends Endocrinol Metab 15(8): 362-9
    › Primary publication · 15380807 (PubMed)
  67. Arcuate nucleus-specific leptin receptor gene therapy attenuates the obesity phenotype of Koletsky (fa(k)/fa(k)) rats. Morton GJ, Niswender KD, Rhodes CJ, Myers MG, Blevins JE, Baskin DG, Schwartz MW (2003) Endocrinology 144(5): 2016-24
    › Primary publication · 12697710 (PubMed)
  68. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Niswender KD, Schwartz MW (2003) Front Neuroendocrinol 24(1): 1-10
    › Primary publication · 12609497 (PubMed)
  69. Immunocytochemical detection of phosphatidylinositol 3-kinase activation by insulin and leptin. Niswender KD, Gallis B, Blevins JE, Corson MA, Schwartz MW, Baskin DG (2003) J Histochem Cytochem 51(3): 275-83
    › Primary publication · 12588955 (PubMed)
  70. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: a key mediator of insulin-induced anorexia. Niswender KD, Morrison CD, Clegg DJ, Olson R, Baskin DG, Myers MG, Seeley RJ, Schwartz MW (2003) Diabetes 52(2): 227-31
    › Primary publication · 12540590 (PubMed)
  71. Intracellular signalling. Key enzyme in leptin-induced anorexia. Niswender KD, Morton GJ, Stearns WH, Rhodes CJ, Myers MG, Schwartz MW (2001) Nature 413(6858): 794-5
    › Primary publication · 11677594 (PubMed)
  72. Mice lacking alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Lu JT, Son YJ, Lee J, Jetton TL, Shiota M, Moscoso L, Niswender KD, Loewy AD, Magnuson MA, Sanes JR, Emeson RB (1999) Mol Cell Neurosci 14(2): 99-120
    › Primary publication · 10532808 (PubMed)
  73. Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. Kupershmidt S, Yang T, Anderson ME, Wessels A, Niswender KD, Magnuson MA, Roden DM (1999) Circ Res 84(2): 146-52
    › Primary publication · 9933245 (PubMed)
  74. Polydactyly and ectopic ZPA formation in Alx-4 mutant mice. Qu S, Niswender KD, Ji Q, van der Meer R, Keeney D, Magnuson MA, Wisdom R (1997) Development 124(20): 3999-4008
    › Primary publication · 9374397 (PubMed)
  75. Cyclosporine-induced autoimmunity in rats carrying thymus allografts. Babcock SK, Niswender K, Wilson DB, Bellgrau D (1990) Transplantation 50(2): 278-81
    › Primary publication · 2382294 (PubMed)
  76. Nuclear changes in ovine luteal cells in response to PGF2 alpha. Sawyer HR, Niswender KD, Braden TD, Niswender GD (1990) Domest Anim Endocrinol 7(2): 229-37
    › Primary publication · 2369821 (PubMed)